Illumina (NASDAQ:ILMN) Price Target Raised to $145.00 at Barclays

Illumina (NASDAQ:ILMN) had its price target hoisted by analysts at Barclays from $135.00 to $145.00 in a research note issued to investors on Tuesday, Benzinga reports. The firm presently has an “equal weight” rating on the life sciences company’s stock. Barclays‘s price objective would suggest a potential downside of 6.26% from the company’s current price.

A number of other equities research analysts also recently issued reports on ILMN. Hsbc Global Res raised Illumina from a “hold” rating to a “strong-buy” rating and set a $180.00 price target for the company in a research report on Thursday, October 17th. Daiwa America raised Illumina to a “strong-buy” rating in a research report on Friday, August 16th. StockNews.com started coverage on Illumina in a research report on Thursday, August 29th. They set a “buy” rating for the company. Daiwa Capital Markets raised Illumina from a “neutral” rating to a “buy” rating and boosted their price target for the company from $120.00 to $154.00 in a research report on Friday, August 16th. Finally, TD Cowen upgraded Illumina from a “hold” rating to a “buy” rating and boosted their price objective for the stock from $126.00 to $144.00 in a research note on Wednesday, August 14th. One analyst has rated the stock with a sell rating, eight have assigned a hold rating, fourteen have assigned a buy rating and two have issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $157.09.

Illumina Trading Up 0.8 %

Shares of NASDAQ:ILMN traded up $1.20 during midday trading on Tuesday, reaching $154.69. The company’s stock had a trading volume of 533,194 shares, compared to its average volume of 1,988,961. The firm has a market cap of $24.64 billion, a price-to-earnings ratio of -7.86 and a beta of 1.13. The company has a quick ratio of 0.86, a current ratio of 1.11 and a debt-to-equity ratio of 1.04. Illumina has a 1 year low of $89.00 and a 1 year high of $155.37. The business has a 50 day moving average price of $136.39 and a 200 day moving average price of $122.65.

Illumina (NASDAQ:ILMN) last announced its quarterly earnings data on Monday, November 4th. The life sciences company reported $1.14 EPS for the quarter, beating analysts’ consensus estimates of $0.88 by $0.26. The business had revenue of $1.08 billion during the quarter, compared to the consensus estimate of $1.08 billion. Illumina had a positive return on equity of 3.08% and a negative net margin of 68.73%. The business’s revenue for the quarter was down 3.5% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.33 earnings per share. Research analysts forecast that Illumina will post 3.62 EPS for the current year.

Institutional Trading of Illumina

Hedge funds and other institutional investors have recently bought and sold shares of the company. Industrial Alliance Investment Management Inc. bought a new stake in Illumina in the second quarter valued at about $34,000. Versant Capital Management Inc increased its holdings in Illumina by 292.9% in the second quarter. Versant Capital Management Inc now owns 330 shares of the life sciences company’s stock valued at $34,000 after buying an additional 246 shares during the last quarter. Massmutual Trust Co. FSB ADV increased its holdings in Illumina by 65.1% in the third quarter. Massmutual Trust Co. FSB ADV now owns 426 shares of the life sciences company’s stock valued at $56,000 after buying an additional 168 shares during the last quarter. Focused Wealth Management Inc bought a new position in shares of Illumina during the third quarter valued at approximately $63,000. Finally, Hollencrest Capital Management acquired a new stake in shares of Illumina during the 3rd quarter worth approximately $63,000. 89.42% of the stock is owned by institutional investors.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.